FLT3 and acute myeloid leukemia: Further, we investigated the binding behavior of clinically approved type-I and type-II AML inhibitors with native and mutant (D835A, D835E, D835F, D835G, D835H, D835I, D835N, D835V, and D835Y) FLT3 by using a molecular docking approach.